Compare Stocks

→ Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$17.82 +0.9%	$15.74	$9.50 ▼ $18.85	$1.61B	1.6	1.22 million shs	774,811 shs
CNCE Concert Pharmaceuticals	$8.37	$8.37	$2.66 ▼ $8.55	$401.26M	0.52	2.97 million shs	N/A
LMNL Liminal BioSciences	$8.50 +0.1%	$8.47	$3.10 ▼ $8.50	$26.35M	1.03	63,470 shs	5,000 shs
UROV Urovant Sciences	$16.24	$16.23	$7.15 ▼ $16.26	$531.75M	2.36	114,469 shs	N/A

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-2.38%	-1.83%	+6.45%	+28.72%	+73.31%
CNCE Concert Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
LMNL Liminal BioSciences	0.00%	0.00%	0.00%	0.00%	+24.63%
UROV Urovant Sciences	0.00%	0.00%	0.00%	0.00%	0.00%

Mysterious Gold Leverage Just Announced (Ad)

World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	3.0335 of 5 stars	4.5	1.0	0.0	0.0	3.4	1.7	0.6
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$22.57	26.66% Upside
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest UROV, LMNL, AVDL, and CNCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$18.00 ➝ $23.00
3/5/2024	AVDL Avadel Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$27.00 ➝ $29.00
3/5/2024	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $25.00
3/5/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
2/6/2024	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$27.96M	57.73	N/A	N/A	$0.98 per share	18.18
CNCE Concert Pharmaceuticals	$32.58M	12.32	N/A	N/A	$3.24 per share	2.58
LMNL Liminal BioSciences	$310K	85.00	N/A	N/A	$8.97 per share	0.95
UROV Urovant Sciences	N/A	N/A	N/A	N/A	($1.90) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$160.28M	-$2.04	N/A	21.47	N/A	N/A	-198.06%	-84.51%	5/2/2024 (Estimated)
CNCE Concert Pharmaceuticals	-$80.05M	-$3.21	N/A	N/A	N/A	N/A	-109.43%	-76.65%	N/A
LMNL Liminal BioSciences	$380K	$0.29	29.31	∞	N/A	248.35%	-88.44%	-64.15%	N/A
UROV Urovant Sciences	-$146.74M	-$4.71	N/A	N/A	N/A	N/A	N/A	-162.90%	N/A

Latest UROV, LMNL, AVDL, and CNCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/4/2024	Q4 2023	AVDL Avadel Pharmaceuticals	-$0.28	-$0.32	-$0.04	-$0.29	$17.41 million	$19.45 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	3.64	3.36
CNCE Concert Pharmaceuticals	N/A	9.03	9.03
LMNL Liminal BioSciences	0.02	2.78	2.78
UROV Urovant Sciences	N/A	2.91	2.91

Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
CNCE Concert Pharmaceuticals	70.63%
LMNL Liminal BioSciences	0.66%
UROV Urovant Sciences	18.44%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.00%
CNCE Concert Pharmaceuticals	11.33%
LMNL Liminal BioSciences	2.20%
UROV Urovant Sciences	2.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	154	90.58 million	86.95 million	Optionable
CNCE Concert Pharmaceuticals	64	47.94 million	42.51 million	Optionable
LMNL Liminal BioSciences	251	3.10 million	3.04 million	Not Optionable
UROV Urovant Sciences	70	32.74 million	N/A	Not Optionable

UROV, LMNL, AVDL, and CNCE Headlines

Source	Headline
	OC Drugmakers Cut Headcounts, Close Offices ocbj.com - April 22 at 7:23 PM
	A2 Bio’s new CEO aims to grow platform pacbiztimes.com - April 8 at 6:15 AM
	C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More biospace.com - March 27 at 2:46 AM
	A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors finance.yahoo.com - March 26 at 3:06 AM
	HEALTH BEHAVIOR AND NUTRITION SCIENCES udel.edu - February 17 at 2:30 PM
	Bulletin Science and Security Board thebulletin.org - February 15 at 3:32 PM
	Secretary-General’s Guidance Note on Behavioural Science un.org - February 5 at 9:35 AM
	Marine Sciences & Technology uml.edu - January 7 at 12:52 PM
	The 7 Best Science Kits for Kids and Teens popularmechanics.com - December 22 at 12:32 AM
	Careers in Computer Science mccormick.northwestern.edu - December 11 at 10:18 AM
	PhD in Information Science drexel.edu - December 8 at 10:01 AM
	Petauri™ Elects William Fleming and James Robinson to Its Board of Directors finance.yahoo.com - December 6 at 10:09 AM
	Core Requirements & Courses bc.edu - December 1 at 1:25 PM
	Inspiring Women in Science nature.com - November 28 at 10:11 AM
	Develop your own cognitive toolkit. miamioh.edu - November 17 at 9:55 AM
	Benign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsight medgadget.com - November 16 at 8:17 AM
	PM360 Announces 2023 Trailblazer Award Winners finance.yahoo.com - October 4 at 8:59 AM
	Heavy Drinking Not Tied to Lower Response to DAAs for Hepatitis C medpagetoday.com - September 26 at 3:23 PM
	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors finance.yahoo.com - September 11 at 8:30 AM
	Clinical and Translational Science Institute buffalo.edu - September 8 at 9:36 PM
	MDxHealth CEO Bullish After Q2 Revenue Boost ocbj.com - September 5 at 8:49 PM
	Windmill Model Science Project education.com - August 15 at 1:51 AM
	Top Science News sciencedaily.com - August 10 at 1:52 PM
	About This Site sciencedaily.com - August 5 at 4:13 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avadel Pharmaceuticals

NASDAQ:AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Concert Pharmaceuticals

NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Liminal BioSciences

NASDAQ:LMNL

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Urovant Sciences

NASDAQ:UROV

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial